» Articles » PMID: 30774631

The Immunology of Macrophage Activation Syndrome

Overview
Journal Front Immunol
Date 2019 Feb 19
PMID 30774631
Citations 314
Authors
Affiliations
Soon will be listed here.
Abstract

Synonymous with secondary hemophagocytic lymphohistiocytosis, macrophage activation syndrome (MAS) is a term used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE). Clinical and laboratory features of MAS include sustained fever, hyperferritinemia, pancytopenia, fibrinolytic coagulopathy, and liver dysfunction. Soluble interleukin-2 receptor alpha chain (sCD25) and sCD163 may be elevated, and histopathology often reveals characteristic increased hemophagocytic activity in the bone marrow (and other tissues), with positive CD163 (histiocyte) staining. A common hypothesis as to the pathophysiology of many cases of MAS proposes a defect in lymphocyte cytolytic activity. Specific heterozygous gene mutations in familial HLH-associated cytolytic pathway genes (e.g., ) have been linked to a substantial subset of MAS patients. In addition, the pro-inflammatory cytokine environment, particularly IL-6, has been shown to decrease NK cell cytolytic function. The inability of NK cells and cytolytic CD8 T cells to lyse infected and otherwise activated antigen presenting cells results in prolonged cell-to-cell (innate and adaptive immune cells) interactions and amplification of a pro-inflammatory cytokine cascade. The cytokine storm results in activation of macrophages, causing hemophagocytosis, as well as contributing to multi-organ dysfunction. In addition to macrophages, dendritic cells likely play a critical role in antigen presentation to cytolytic lymphocytes, as well as contributing to cytokine expression. Several cytokines, including tumor necrosis factor, interferon-gamma, and numerous interleukins (i.e., IL-1, IL-6, IL-18, IL-33), have been implicated in the cytokine cascade. In addition to broadly immunosuppressive therapies, novel cytokine targeted treatments are being explored to dampen the overly active immune response that is responsible for much of the pathology seen in MAS.

Citing Articles

Advances in Interleukin-6 Family Cytokines and the Role in Respiratory Diseases.

Ji T, Huang G, Cao Y, Gao Y, Gao X J Inflamm Res. 2025; 18:3125-3141.

PMID: 40059944 PMC: 11889408. DOI: 10.2147/JIR.S508031.


Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.

Peng Z, Zhou G Front Immunol. 2025; 16:1551122.

PMID: 40046058 PMC: 11879827. DOI: 10.3389/fimmu.2025.1551122.


Subacute liver injury in two young infants following gene replacement therapy for spinal muscular atrophy.

Ables C, Jaramillo C, Wood E, Stern S, Alashari M, Book L Mol Ther Methods Clin Dev. 2025; 32(3):101296.

PMID: 40017665 PMC: 11866129. DOI: 10.1016/j.omtm.2024.101296.


Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis.

Brossard P Clin Transl Sci. 2025; 18(2):e70163.

PMID: 39943917 PMC: 11822261. DOI: 10.1111/cts.70163.


Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease.

Shi J, Pei X, Peng J, Wu C, Lv Y, Wang X Clin Transl Med. 2025; 15(2):e70226.

PMID: 39902678 PMC: 11791760. DOI: 10.1002/ctm2.70226.


References
1.
Netea M, Kullberg B, Verschueren I, van der Meer J . Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1beta. Eur J Immunol. 2000; 30(10):3057-60. DOI: 10.1002/1521-4141(200010)30:10<3057::AID-IMMU3057>3.0.CO;2-P. View

2.
Alkoht A, Hanafi I, Khalil B . Macrophage Activation Syndrome: A Report of Two Cases and a Literature Review. Case Rep Rheumatol. 2017; 2017:5304180. PMC: 5676417. DOI: 10.1155/2017/5304180. View

3.
Lasiglie D, Traggiai E, Federici S, Alessio M, Buoncompagni A, Accogli A . Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients. PLoS One. 2011; 6(5):e20014. PMC: 3102666. DOI: 10.1371/journal.pone.0020014. View

4.
Ravelli A, De Benedetti F, Viola S, Martini A . Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996; 128(2):275-8. DOI: 10.1016/s0022-3476(96)70408-0. View

5.
Zhang M, Behrens E, Atkinson T, Shakoory B, Grom A, Cron R . Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep. 2014; 16(9):439. DOI: 10.1007/s11926-014-0439-2. View